CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 163,720 enrolled
Drug / intervention
Dihydropyridine calcium channel blocker +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05125224
NCT05125224N/ACompleted
CompareCT.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide

Brigham and Women's Hospital·observational·Posted Nov 18, 2021·Updated Nov 6, 2025

In Brief

An observational study evaluating Dihydropyridine calcium channel blocker and Hydrochlorothiazide for Hypertension. Completed, enrolled 163,720 participants across 1 site.

Detailed Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Rutgers University, Johns Hopkins University

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 18, 2021
Enrollment StartOct 1, 2021
Primary CompletionJul 7, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.6 years ago

Interventions

Dihydropyridine calcium channel blockerdrug

Dihydropyridine calcium channel blocker claim is used as the exposure group.

Hydrochlorothiazidedrug

Hydrochlorothiazide claim is used as the reference group.